Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1380.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1186.0,1.0,=,1.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1963.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1852.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1010.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,833.0,1.0,=,1.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1305.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,779.0,1.0,=,1.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1879.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2395.0,1.0,=,0.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2028.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1990.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,856.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,579.0,1.0,=,1.5